Articles
Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer
Breast cancer is the most common type of cancer and the leading cause of cancer deaths in women worldwide (Sung 2021). In 2020, there were approximately 2.3 million new cases of breast cancer and 683,100 deaths
Adjuvant and neoadjuvant chemotherapy improve survival; however, 30% to 40% of early‐stage TNBC cases progress to metastatic disease. Recent evidence suggests that combining immune checkpoint inhibitors (PD‐1/PD‐L1 inhibitors) with chemotherapy may improve pathological complete response and event‐free survival.
Click here to access the article.